Find uplifting stories about heroes, innovations, and solutions
5 results for "kisunla"
Patients with early Alzheimer's now have access to Kisunla, an FDA-approved therapy that slows disease progression and helps people maintain independence longer. UToledo Health is offering the treatment, marking a major shift from managing symptoms to actually slowing the disease itself.
Stormont Vail Health in Topeka will start offering Kisunla next week, becoming the fourth Kansas facility to provide the FDA-approved therapy that slows early Alzheimer's progression. The treatment has shown promising results in helping patients preserve their independence longer.
Health Canada has authorized Kisunla, a breakthrough treatment that slows early Alzheimer's progression by 22% and can be stopped once brain plaques clear. Over 770,000 Canadians living with Alzheimer's now have access to the first disease-modifying therapy that targets the root cause of memory loss.
A Florida grandfather completed an 18-month Alzheimer's treatment that cleared the amyloid plaques from his brain, bringing hope to families facing this devastating disease. While not a cure, the breakthrough therapy slowed disease progression and helped him return to fishing, traveling, and cherishing moments with his grandson.
Scientists discovered that a single brain protein called SORLA protects against both toxic plaques and tangles that destroy brain cells in Alzheimer's disease. Mice with higher SORLA levels showed less brain damage and healthier neurons, offering new hope for treating dementia.